Metabasis Announces Completion Of Enrollment In The Phase 2b Clinical Trial For CS-917 In Patients With Type 2 Diabetes
Fri, 02 Feb 2007 08:00 AM EST
... Metabasis Therapeutics (Nasdaq: MBRX) today announced that enrollment was recently completed in the ongoing Phase 2b clinical trial for CS-917, a compound being developed for the treatment of type 2 diabetes by Daiichi Sankyo pursuant to a licensing agreement between the two companies. [click link for full article] ...
Related Topics
- Clinical Trials
- Diabetes - Type 1
- Diabetes - Type 2
- Juvenile Diabetes
- Diabetes and Pregnancy
- Diabetes Insipidus
- Gestational Diabetes
- Ribavirin and Interferon alfa-2b, recombinant
- Pharmacology
- Trastuzumab
- Psychopharmacology
- Epidemiology
- Tarceva
- Interferon Alfa-2b
- Diabetes
- Type 1 diabetes
- Type 2 diabetes
- Diabetes Type 1
- Peginterferon alfa-2b
- Food Recommendations: South Beach Diet - Phase 1

Not Signed In -

